Quarterly report pursuant to Section 13 or 15(d)

Segments

v3.10.0.1
Segments
6 Months Ended
Jun. 30, 2018
Segment Reporting [Abstract]  
SEGMENTS
SEGMENTS
We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations we acquired in Chile, Mexico, Ireland, Israel and Spain and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical laboratory operations we acquired through the acquisition of BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 
For the three months ended June 30,
 
For the six months ended June 30,
(In thousands)
2018
 
2017
 
2018
 
2017
Revenue from services:
 
 
 
 
 
 
 
Pharmaceutical
$

 
$

 
$

 
$

Diagnostics
216,055

 
233,912

 
427,369

 
462,456

Corporate

 

 

 

 
$
216,055

 
$
233,912

 
$
427,369

 
$
462,456

Revenue from products:
 
 
 
 
 
 
 
Pharmaceutical
$
28,523

 
$
28,966

 
$
56,374

 
$
51,197

Diagnostics

 

 

 

Corporate

 

 

 

 
$
28,523

 
$
28,966

 
$
56,374

 
$
51,197

Revenue from transfer of intellectual property and other:
 
 
 
 
 
 
 
Pharmaceutical
$
19,107

 
$
29,723

 
$
34,855

 
$
45,328

Diagnostics

 

 

 

Corporate

 

 

 

 
$
19,107

 
$
29,723

 
$
34,855

 
$
45,328

Operating loss:
 
 
 
 
 
 
 
Pharmaceutical
$
2,165

 
$
(8,009
)
 
$
(20,783
)
 
$
(34,154
)
Diagnostics
1,475

 
(4,944
)
 
(6,543
)
 
(8,044
)
Corporate
(8,748
)
 
(12,878
)
 
(20,393
)
 
(28,849
)
 
$
(5,108
)
 
$
(25,831
)
 
$
(47,719
)
 
$
(71,047
)
Depreciation and amortization:
 
 
 
 
 
 
 
Pharmaceutical
$
6,752

 
$
6,694

 
$
13,492

 
$
13,469

Diagnostics
17,989

 
18,827

 
35,975

 
37,752

Corporate
21

 
30

 
51

 
60

 
$
24,762

 
$
25,551

 
$
49,518

 
$
51,281

Loss from investment in investees:
 
 
 
 
 
 
 
Pharmaceutical
$
(6,942
)
 
$
(5,309
)
 
$
(9,114
)
 
$
(7,123
)
Diagnostics
(271
)
 
(319
)
 
(555
)
 
(635
)
Corporate

 

 

 

 
$
(7,213
)
 
$
(5,628
)
 
$
(9,669
)
 
$
(7,758
)
Revenues:
 
 
 
 
 
 
 
United States
$
222,535

 
$
244,650

 
$
437,845

 
$
474,084

Ireland
20,778

 
22,525

 
38,060

 
39,734

Chile
11,937

 
11,899

 
23,670

 
22,020

Spain
4,592

 
5,118

 
10,125

 
9,623

Israel
2,526

 
7,654

 
6,141

 
11,872

Mexico
1,302

 
724

 
2,723

 
1,589

Other
15

 
31

 
34


59

 
$
263,685

 
$
292,601

 
$
518,598

 
$
558,981


(In thousands)
June 30,
2018
 
December 31,
2017
Assets:
 
 
 
Pharmaceutical
$
1,258,293

 
$
1,287,964

Diagnostics
1,217,456

 
1,241,388

Corporate
55,201

 
60,604

 
$
2,530,950

 
$
2,589,956

Goodwill:

 

Pharmaceutical
$
261,447

 
$
264,313

Diagnostics
452,787

 
452,786

Corporate

 

 
$
714,234

 
$
717,099



One customer represented more than 10% of our total consolidated revenue during the three months ended June 30, 2018 and two customers represented more than 10% of our total consolidated revenue during the six months ended June 30, 2018. One customer represented more than 10% of our total consolidated revenue during the three and six months ended June 30, 2017. As of June 30, 2018, one customer represented more than 10% of our accounts receivable balance. As of December 31, 2017, no customer represented more than 10% of our accounts receivable balance.